

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10354 A2(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/CA01/01118

(22) International Filing Date: 1 August 2001 (01.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,313,828 1 August 2000 (01.08.2000) CA

(71) Applicant (for all designated States except US): INSTITUT DE RECHERCHE CLINIQUES DE MONTREAL (IRCM) [CA/CA]; Dépt. de Neuroendocrinologie Biochimique, 110, avenue des Pins Ouest, Montréal, Quebec H2W 1R7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SEIDAH, Nabil, G. [CA/CA]; Ile des Soeurs, 200 de Gaspé #1412, Verdun, Quebec H3E 1E6 (CA). CHRETIEN, Michel [CA/CA]; 195 Côte-Ste-Catherine #2208, Outremont, Quebec H2V 2B1 (CA). CROMLISH, James, A. [CA/CA]; 5377, Saint Ignatius Street, Montreal, Quebec H4C 2C5 (CA).

(74) Agents: DUBUC, J. et al.; Goudreau Gage Dubuc, Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: SECRETASE/SHEDDASE WITH ASP-ASE ACTIVITY ON THE BETA-SITE APP-CLEAVING ENZYME (BACE, ASP2, MEMEPSIN 2)



(57) Abstract: A novel Asp-ase activity, referred to as BACE secretase/sheddase, has been found to cleave the ectodomain of BACE after Asp₃₇₉ (SQDD↓) and Asp₄₀₇ (VVFD↓), and likely after Asp₄₅₁ (PQTD↓). The cleavage of BACE by BACE secretase/sheddase renders BACE soluble which in turn appears to enhance the generation of the amyloidogenic peptide Aβ, which has been implicated as a major factor in the etiology of Alzheimer's Disease. The current invention concerns the modulation of this novel BACE secretase/sheddase activity for such applications as the prevention or treatment of a neurodegenerative disorder that is characterized by the generation of Aβ protein, including Alzheimer's Disease. The invention further comprises a method for the identification of an agent that can alter the ability of BACE secretase/sheddase to associate with and process a known substrate, a method of determining whether an individual is at risk of developing a neurodegenerative disorder that is characterized by the generation of Aβ protein (such as Alzheimer's Disease) and a kit comprising a vessel or vessels containing BACE secretase/sheddase as well as at least one known substrate of this enzyme, namely, BACE or BACE fragments, or the indirect substrate βAPP.

BEST AVAILABLE COPY



— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE OF THE INVENTION

5 Secretase / sheddase with Asp-ase activity on the beta-site APP-cleaving
enzyme (BACE, Asp2, memepsin 2)

FIELD OF THE INVENTION

10 The present invention relates to β -secretase referred to as the beta-site APP-
cleaving enzyme (BACE, Asp2, memepsin 2). More specifically, the present
invention concerns a novel Asp-ase that processes BACE, referred to as BACE
secretase / sheddase, and the use of this enzyme in the diagnosis, prevention or
treatment of neurodegenerative disorders, such as Alzheimer's Disease. The present
15 invention further comprises the use of BACE secretase / sheddase in a screening assay
for the identification of agents capable of modifying its activity (modulating agents)
as well as the use of BACE secretase / sheddase in a kit.

BACKGROUND OF THE INVENTION

20 Alzheimer Disease (AD) is a progressive degenerative disorder of the brain
characterized by mental deterioration, memory loss, confusion, and disorientation. Among
the cellular mechanisms contributing to this pathology are two types of fibrous protein
deposition in the brain: intracellular neurofibrillary tangles composed of polymerized tau
25 protein, and abundant extracellular fibrils comprised largely of β -amyloid (for reviews, see
1-3). Beta-amyloid, also known as $A\beta$, arises from proteolytic processing of the β -amyloid
precursor protein (β APP) at the β - and γ -secretase cleavage sites. The cellular toxicity and
amyloid-forming capacity of the two major forms of $A\beta$ ($A\beta_{40}$ and especially $A\beta_{42}$) have
30 been well documented (1-3).

An alternative anti-amyloidogenic cleavage site performed by α -secretase is located within the A β peptide sequence of β APP and thus precludes formation of intact insoluble A β . Cleavage by α -secretase within the [HisHisGlnLys↓LeuVal] sequence of β APP is the major physiological route of maturation. The products of this reaction are a soluble 100-120 kDa N-terminal fragment (β APPs α) and a C-terminal membrane-bound ~9 kDa segment (C83). In several recent reports, metalloproteinases such as ADAM9, 10 and 17 were shown to be involved in the α -secretase cleavage of β APP (4-6). Enzymes within this family are typically synthesized as inactive zymogens that subsequently undergo prodomain cleavage and activation in the *trans* Golgi network (TGN). To date, several of the ADAMs have been shown to be activated in a non-autocatalytic manner by other enzymes such as the proprotein convertases (PCs) (7). Thus, it is conceivable that such enzymes may participate in a cascade leading to the activation of α -secretase. In support of this proposal, it has been recently demonstrated that inhibition of PC-like enzymes in HK293 cells by the α 1-antitrypsin serpin variant α 1-PDX (8) blocks the α -secretase cleavage of β APP_{sw} (9). Correspondingly, overexpression of a PC (e.g., PC7) increases α -secretase activity. Of the above-mentioned candidate α -secretases, ontogeny and tissue-expression analyses suggest that, in adult human and/or mouse brain neurons, ADAM10 is a more plausible α -secretase than ADAM17 (10).

The amyloidogenic pathway of β APP processing begins with β -secretase. This enzyme(s) generates the N-terminus of A β by cleaving β APP within the GluValLysMet↓AspAla sequence (SEQ ID NO :1), or by cleaving the Swedish mutant β APP_{sw} within the GluValAsnLeu↓AspAla sequence (SEQ ID NO :2). In addition, some cleavage was reported to occur within the A β sequence AspSerGlyTyr₁₀↓Glu₁₁Val (SEQ ID NO :3) generating A β _{11-40/42} (11). Very recently, five different groups simultaneously reported the isolation and initial characterization of two novel human aspartyl proteinases, BACE (11-15) and its closely related homologue BACE2 (14,15). BACE appears to fulfill all of the criteria of being a β -

secretase. While *in vitro* cleavage specificity analyses of BACE and BACE2 did not reveal clear consensus recognition sequences (11,15) they did lead to the development of novel modified statine inhibitors (13). Comparative modeling of the three-dimensional structure of BACE as a complex with its substrate suggested that BACE would preferentially cleave substrates having a negatively charged residue at P1' and a hydrophobic residue at P1 (16), which is the case for the β -secretase site in β APP, β APP_{sw} and in the generation of the A β ₁₁₋₄₀ peptide. Both BACE and BACE2 are type-I membrane-bound proteins with a prodomain that, at least for BACE (12), is rapidly cleaved intracellularly. However, little else is known about the mechanism of zymogen processing of these enzymes, including whether their activation is autocatalytic or carried out by other enzymes. Recent data derived from BACE overexpressed in bacteria (15) suggested that zymogen processing of the prosegment's R₄₂LPR₄₅↓ site, which is reminiscent of PC-cleavage sites (7), is not autocatalytic; rather it is effected by another proteinase(s). Finally, developmental analysis of the comparative tissue expression of mouse BACE and BACE2 suggested that BACE, but not BACE2, is a good candidate β -secretase in the brain (10).

The second step in the amyloidogenic pathway of β APP maturation involves cleavages at the γ -secretase sites (ValVal↓IleAla↓ThrVal) (SEQ ID NO :4) to generate either A β ₄₀ or A β ₄₂. Recently, in neuronal N2a cells, A β ₄₀ was shown to be produced within the TGN and subsequently packaged into post-TGN secretory vesicles, suggesting that the TGN is the major intracellular compartment within which the A β ₄₀-specific γ -secretase is active (17). Although some insoluble, N-terminally truncated A β _{x-42} originates in the endoplasmic reticulum (ER), A β ₄₂ and A β ₄₀ are formed primarily in the TGN which comprises the major source of the constitutively secreted pool of A β that is deposited as extracellular amyloid plaques. Moreover, the generation of either peptide requires that β APP or its membrane-bound, β -secretase cleavage product C99, passes at least once through endosomal compartments (18). Thus, β APP trafficking to or retention in particular cellular compartments may

critically influence its processing. While the identification of the γ -secretase(s) has not yet been conclusively established (18), some reports have suggested that presenilins are possible candidates (19).

5 SUMMARY OF THE INVENTION

In the studies leading to the current invention, PCs were investigated to determine whether they are responsible for the cleavage of the prosegment of BACE, as well as the consequences of blocking this maturation. In addition, several post-
10 translational modifications of BACE and their possible influence on the processing of β APP and the generation of amyloidogenic A β peptides were examined.

The research data obtained indicate that compared to similar levels of expression of full length BACE, expression of a soluble form of beta-APP converting
15 enzyme (BACE_S), prepared by deleting the transmembrane domain and cytosolic tail, results in a very significant increase in the levels of A β peptide produced from the Swedish mutant of APP. In contrast, overexpression of full-length BACE (BACE_F) in HK293 cells causes a significant increase in C99. In fact, evidence for BACE C-terminal proteolytic cleavage / shedding is provided, as shown by the detection of
20 apparent 34, 15, 11 and 6 kDa BACE fragments (Fig. 5C, Fig. 7, Fig. 8, Fig. 10, Fig. 11), and BACE shed into the media (Fig. 9). Therefore, BACE_F is transformed into C-terminal truncated forms similar to BACE_S.

A unique C-terminal proteolytic cleavage of BACE by a novel Asp-ase
25 activity (referred to as BACE secretase / sheddase activity) has been identified. Recent data on the characterization of the nature of BACE C-terminal cleavage reveals this novel BACE secretase / sheddase activity. Since truncation of BACE

leads to increased A β production, BACE secretase / sheddase is an attractive target to modulate for medicinal and research purposes.

5 The current invention concerns the modulation of this novel BACE secretase / sheddase activity for such applications as the prevention or treatment of a neurodegenerative disorder that is characterized by the generation of A β protein, including Alzheimer's Disease. The invention further comprises a method for the identification of an agent that can alter the ability of BACE secretase / sheddase to associate with and process a known substrate, a method of determining whether an
10 individual is at risk of developing a neurodegenerative disorder that is characterized by the generation of A β protein (such as Alzheimer's Disease) and a kit comprising a vessel or vessels containing BACE secretase / sheddase as well as at least one known substrate of this enzyme, namely, BACE or BACE fragments, or the indirect substrate β APP.

15 An object of the present invention is therefore the inhibition of A β plaque formation in such neurodegenerative disorders as Alzheimer's Disease through the modulation of the newly-identified BACE secretase / sheddase activity in order to treat and/or prevent the progression of this disease.

20 A further object of the present invention is to make use of the newly-identified BACE secretase / sheddase activity in a screening assay, in a diagnostic assay for neurodegenerative disorders characterized by the generation of A β protein (such as Alzheimer's Disease) and in a kit.

25

DESCRIPTION OF THE DRAWINGS

Figure 1: HK293 cells were transiently co-transfected with either ([BACE_F]_{FG/V5} +
5 BDNF) [control, CTL] (A,C) or ([BACE_F]_{FG/V5} + α 1-PDX) (B,D) cDNAs. Two days
post-transfections the cells were pulse-labeled in the absence or presence of 5 mM
BFA for 15 min with [³⁵S]Met and then chased for 1 or 2h. Cell lysates were
immunoprecipitated with either the FG or V5 mAbs and analysed by SDS-PAGE on
8% tricine gels. The migration position of the 53 kDa molecular mass standard and
10 those of proBACE (pBACE) and BACE are emphasized.

Figure 2: [A] HK293 cells were transiently co-transfected with cDNAs coding for
either ([BACE_F]_{FG/V5} + BDNF) [control, CTL], ([BACE_F-R45A]_{FG/V5} + BDNF) or
([BACE_F-R42A]_{FG/V5} + BDNF) or ([BACE_F]_{FG/V5} + either α 1-PDX, the prosegments
15 of furin, PC5, PC7, SKI-1, furin-mutated (α 2M-F) or wild type (α 2M) α 2-
macroglobulin. The cells were pulse-labeled for 20 min with [³⁵S]Met and then
chased for 90 min. Cell lysates were immunoprecipitated with the FG mAb and
analysed by SDS-PAGE on 8% tricine gels. [B] HK293 cells were transiently co-
transfected with cDNAs coding for either ([BACE_F]_{FG/V5} + BDNF) [CTL],
20 ([BACE_F]_{FG/V5} + furin) or ([BACE_F]_{FG/V5} + α 1-PDX). The cells were then pulse-
labeled for 2h with Na₂[³⁵SO₄]. Cell lysates were immunoprecipitated with the FG or
V5 mAbs and analysed by SDS-PAGE on 8% tricine gels. (The higher apparent size
of BACE_G in the CTL lane compared to the furin lane is due to end-lane distortion.)
The migration positions of those proBACE in the ER (pBACE_{ER}) or Golgi (pBACE_G)
25 are emphasized.

Figure 3: Western blot analysis of 1-4h *in vitro* processing of wild type (WT)
[proBACE_S]_{FG/V5} or the (R45A) mutant [proBACE_S-R45A]_{FG/V5} by either furin, PC5-
A, PACE4 or PC7 in the absence or presence of 1 μ M of PC-prosegments (pPCs).
30 Flag-M2 (FG) or V5-HRP monoclonal antibodies were used.

Figure 4: [A] HK293 cells were transiently transfected with cDNAs coding for either [BACE_F]_{FG}, [BACE_F-Δp]_{FG} or [BACE_S]_{V5}. The cells were pulse-labeled for 20 min (-) with [³⁵S]Met and then chased for 1h or 2h. Cell lysates and media (for BACE_S) were immunoprecipitated with the FG or V5 mAbs and analysed by SDS-PAGE on 8% tricine gels. [B] HK293 cells were transiently transfected with [BACE_S]_{V5} cDNA. The cells were then pulse-labeled for 2h. with Na₂[³⁵SO₄]. Cell lysates were immunoprecipitated with the V5 mAb. Equal aliquots of SDS-PAGE-purified proteins were then digested overnight at 37°C with 5 mU of either endoH or endoF (Glyko Inc.) or 80 mU of arylsulfatase (ASase; Sigma). The products were analysed by SDS-PAGE on 8% tricine gels. [C] HK293 cells were transiently transfected with cDNAs coding for either [BACE_F]_{FG}, [BACE_F-C482,485A]_{FG}, [BACE_F-C478,482,485A]_{FG}, [BACE_F-Δp]_{FG} or [BACE_S]_{V5}. The cells were pulse-labeled for 2h with [³H]palmitic acid. Cell lysates were immunoprecipitated with FG or V5 (for BACE_S) mAbs and analysed by SDS-PAGE on 8% tricine gels.

Figure 5: HK293 cells were transiently transfected with cDNAs coding for either [A,B] (BDNF + βAPP_{sw}) [CTL] or ([BACE_F]_{FG} + βAPP_{sw}), [C] [BACE_F]_{FG} or [BACE_S]_{FG}. The cells were pulse-labeled for 3h with [³⁵S]Met at either 37°C in the absence or presence of 90 μM BFA or 250 nM bafilomycin or at 20°C. Cell lysates were immunoprecipitated with either [A] the FG mAb or [B] the 1-16 Aβ antibody, and analysed by SDS-PAGE on 8% tricine gels. [C] FG antibody, and analysed by SDS-PAGE on 8% tricine gels. The arrowhead point to an ~6 kDa intracellular stub of BACE_F.

Figure 6: HK293 cells were transiently co-transfected with cDNAs coding for (βAPP_{sw} + BDNF) [-], or βAPP_{sw} together with either [BACE_S]_{V5}, [BACE_F]_{FG}, [BACE_F-D93A]_{FG}, [BACE_F-R45A]_{FG}, or [BACE_F-Δp]_{FG}. The cells were pulse-labeled for 3h with [³⁵S]Met. The cell lysates [A] or media [B,C] were immunoprecipitated [A,C] with the 1-16 Aβ antibody, and in [B] with the 1-40 Aβ antibody (A8326), and

analysed by SDS-PAGE on 8% [A,C] or 14% [B] tricine gels. The migration positions of C99, A β , A β_{x-40} APPs and A β_{17-40} known as p3 (generated by α - and γ -secretases) are shown.

- 5 **Figure 7:** HK293 cells were transiently transfected with cDNAs coding for either [BACE_F]_{FG} or an empty pIRES vector [control, CTL]. Following a 4 hr pulse with ³⁵S-Met cell lysates were immunoprecipitated with FG antibodies, denatured in the presence [reduced] or absence [non-reduced] of 2-mercaptoethanol and subsequently analysed by SDS-PAGE on 8% tricine gels. The arrow heads point to apparent
10 BACE_F cleavage products of 34, 15, 11 and 6 kDa. The exposure time was 8 hours.

- Figure 8:** [A] Neuro 2a APP_{SW} cells were transiently transfected with cDNA for [BACE_F]_{FG}. Cells were labeled with ³⁵S-Met for 3 hrs in the absence (-, DMSO control) or presence of 100 uM of a substrate based γ -secretase inhibitor (+ γ -sec I,
15 DFK-167 Enzyme Systems products). Cell lysates were immunoprecipitated with FG antibodies, reduced and analyzed by SDS-PAGE on 8% tricine gels. Cell lysates [B] and media [C] were immunoprecipitated with antibody APP711-03 and analyzed by SDS-PAGE on 8% tricine gels. [D] Media was immunoprecipitated with the 1-40 A β antibody and analyzed on a 14% tricine gel. The exposure time was 3 days.

20

- Figure 9:** Neuro 2a APP_{SW} cells were transiently transfected with cDNAs for [BACE_F]_{FG}, [BACE_S]_{VS}, or the pIRES control [CTL]. Media and cells were analyzed by immunoprecipitation with an antibody to BACE (BACE 41 – Research Genetics, described in Materials and Methods) following a 3 hr chase with ³⁵S-Met. The SDS-
25 PAGE 8% tricine gels were exposed to film for 5 hrs. The positions of BACE_S in the media, and the cellular 34 and 15 kDa bands are indicated.

Figure 10: HK293 cells were transiently transfected with cDNA for [BACE_F]_{FG}. Cells were labeled with ³⁵S-Met or ³H-Phenylalanine for 3 hrs as indicated. Following

immunoprecipitation with FG antibodies, the 15 kDa BACE fragment (see Fig. 7) was purified by preparative SDS-PAGE and extracted. Radiosequencing was performed as described under Materials and Methods. The amino acid sequence of BACE starting at Gln₃₅₅ and encompassing the N-terminus of the 15 kDa BACE fragment is shown.

5

Figure 11: HK293 cells were transiently transfected with cDNA for [BACE_F]_{FG}. Cells were labeled with ³H-Phenylalanine for 3 hrs as indicated. Following immunoprecipitation with FG antibodies, the 11 kDa BACE fragment (see Fig. 7) was purified by preparative SDS-PAGE, extracted and radiosequencing was performed. The amino acid sequence of BACE starting at Met₃₉₄ and encompassing the N-terminus of the 11 kDa BACE fragment is shown.

10

DETAILED DESCRIPTION

15

In order to provide a clear and consistent understanding of terms used in the present description, a number of definitions are provided hereinbelow.

20

Unless defined otherwise, the scientific and technological terms and nomenclature used herein have the same meaning as commonly understood by a person of ordinary skill to which this invention pertains. Generally, the procedures for cell cultures, infection, molecular biology methods and the like are common methods used in the art. Such standard techniques can be found in reference manuals such as for example Sambrook et al. (1989, Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratories) and Ausubel et al. (1994, Current Protocols in Molecular Biology, Wiley, New York).

25

30

Polymerase chain reaction (PCR) is carried out in accordance with known techniques. See, e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; and 4,965,188 (the disclosures of all three U.S. Patent are incorporated herein by reference). In

general, PCR involves, a treatment of a nucleic acid sample (e.g., in the presence of a heat stable DNA polymerase) under hybridizing conditions, with one oligonucleotide primer for each strand of the specific sequence to be detected. An extension product of each primer which is synthesized is complementary to each of the two nucleic acid strands, with the primers sufficiently complementary to each strand of the specific sequence to hybridize therewith. The extension product synthesized from each primer can also serve as a template for further synthesis of extension products using the same primers. Following a sufficient number of rounds of synthesis of extension products, the sample is analyzed to assess whether the sequence or sequences to be detected are present. Detection of the amplified sequence may be carried out by visualization following EtBr staining of the DNA following gel electrophores, or using a detectable label in accordance with known techniques, and the like. For a review on PCR techniques (see PCR Protocols, A Guide to Methods and Amplifications, Michael et al. Eds, Acad. Press, 1990).

As used herein, the term "gene" is well known in the art and relates to a nucleic acid sequence defining a single protein or polypeptide. A "structural gene" defines a DNA sequence which is transcribed into RNA and translated into a protein having a specific amino acid sequence thereby giving rise to a specific polypeptide or protein. It will be readily recognized by the person of ordinary skill, that the nucleic acid sequence of the present invention can be incorporated into anyone of numerous established kit formats which are well known in the art.

The term "vector" is commonly known in the art and defines a plasmid DNA, phage DNA, viral DNA and the like, which can serve as a DNA vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.

The term "expression" defines the process by which a gene is transcribed into mRNA (transcription), the mRNA is then being translated (translation) into one polypeptide (or protein) or more.

5 The terminology "expression vector" defines a vector or vehicle as described above but designed to enable the expression of an inserted sequence following transformation into a host. The cloned gene (inserted sequence) is usually placed under the control of control element sequences such as promoter sequences. The placing of a cloned gene under such control sequences is often referred to as being
10 operably linked to control elements or sequences.

 The DNA construct can be a vector comprising a promoter that is operably linked to an oligonucleotide sequence of the present invention, which is in turn, operably linked to a heterologous gene, such as the gene for the luciferase reporter
15 molecule. "Promoter" refers to a DNA regulatory region capable of binding directly or indirectly to RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of the present invention, the promoter is bound at its 3' terminus by the transcription initiation site and extends upstream (5'
20 direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter will be found a transcription initiation site (conveniently defined by mapping with S1
nuclease), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CCAT" boxes. Prokaryotic promoters contain -10 and -
25 35 consensus sequences, which serve to initiate transcription and the transcript products contain Shine-Dalgarno sequences, which serve as ribosome binding sequences during translation initiation.

As used herein, the terms "molecule", "compound", "agent" or "ligand" are used interchangeably and broadly to refer to natural, synthetic or semi-synthetic molecules or compounds. The term "molecule" therefore denotes for example chemicals, macromolecules, cell or tissue extracts (from plants or animals) and the like. Non limiting examples of molecules include nucleic acid molecules, peptides, antibodies, carbohydrates and pharmaceutical agents. The agents can be selected and screened by a variety of means including random screening, rational selection and by rational design using for example protein or ligand modeling methods such as computer modeling. As will be understood by the person of ordinary skill, macromolecules having non-naturally occurring modifications are also within the scope of the term "molecule". For example, peptidomimetics, well known in the pharmaceutical industry and generally referred to as peptide analogs can be generated by modeling as mentioned above. Similarly, in a preferred embodiment, the polypeptides of the present invention are modified to enhance their stability. It should be understood that in most cases this modification should not alter the biological activity of the interaction domain.

As used herein, the term "BACE fragments" refers to stretches of BACE amino acid sequence that contain the BACE secretase / sheddase cleavage sites defined more particularly below.

As used herein, agonists and antagonists of BACE sheddase / secretase interaction (discussed further below) also include potentiators of known compounds with such agonist or antagonist properties. In one embodiment, agonists can be detected by contacting the indicator cell with a compound or mixture or library of molecules for a fixed period of time is then determined.

In general, techniques for preparing antibodies (including monoclonal antibodies and hybridomas) and for detecting antigens using antibodies are well known in the art (Campbell, 1984, In "Monoclonal Antibody Technology:

Laboratory Techniques in Biochemistry and Molecular Biology", Elsevier Science Publisher, Amsterdam, The Netherlands) and in Harlow et al., 1988 (in: Antibody- A Laboratory Manual, CSH Laboratories). The present invention also provides polyclonal, monoclonal antibodies, or humanized versions thereof, chimeric
5 antibodies and the like which inhibit or neutralize their respective interaction domains and/or are specific thereto.

From the specification and appended claims, the term therapeutic agent should be taken in a broad sense so as to also include a combination of at least two such
10 therapeutic agents. Further, the DNA segments or proteins according to the present invention can be introduced into individuals in a number of ways. For example, neuronal cells can be isolated from the afflicted individual, transformed with a DNA construct according to the invention and reintroduced to the afflicted individual in a number of ways, including intravenous injection. Alternatively, the DNA construct
15 can be administered directly to the afflicted individual, for example, by injection in the bone marrow. The DNA construct can also be delivered through a vehicle such as a liposome, which can be designed to be targeted to a specific cell type, and engineered to be administered through different routes.

20 For administration to humans, the prescribing medical professional will ultimately determine the appropriate form and dosage for a given patient, and this can be expected to vary according to the chosen therapeutic regimen (e.g. DNA construct, protein, cells), the response and condition of the patient as well as the severity of the disease.

25 Composition within the scope of the present invention should contain the active agent (e.g. fusion protein, nucleic acid, and molecule) in an amount effective to achieve the desired therapeutic effect while avoiding adverse side effects. Typically, the nucleic acids in accordance with the present invention can be administered to

mammals (e.g. humans) in doses ranging from 0.005 to 1 mg per kg of body weight per day of the mammal which is treated. Pharmaceutically acceptable preparations and salts of the active agent are within the scope of the present invention and are well known in the art (Remington's Pharmaceutical Science, 16th Ed., Mack Ed.). For the
5 administration of polypeptides, antagonists, agonists and the like, the amount administered should be chosen so as to avoid adverse side effects. The dosage will be adapted by the clinician in accordance with conventional factors such as the extent of the disease and different parameters from the patient. Typically, 0.001 to 50 mg/kg/day will be administered to the mammal.

10 The invention provides efficient methods of identifying pharmacological agents or lead compounds for agents capable of mimicking or modulating BACE secretase / sheddase function and preventing the production of the A β peptide. Identified reagents find use in the pharmaceutical industries for animal and human
15 trials; for example, the reagents may be derived and rescreened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

20 Agents that could be used to manipulate the function of BACE secretase / sheddase include specific antibodies that can be modified to a monovalent form, such as Fab, Fab', or Fv, specifically binding oligopeptides or oligonucleotides and most preferably, small molecular weight organic receptor agonists. See, Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, for general methods. Anti-idiotypic antibody, especially internal imaging anti-ids are also
25 prepared using the disclosures herein.

Other prospective BACE secretase / sheddase specific agents are screened from large libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of saccharide, peptide, and nucleic

acid based compounds. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily producible. Additionally, natural and synthetically produced libraries and compounds are readily modified through conventional chemical, physical, and biochemical means. See, e.g.
5 Houghten et al. and Lam et al (1991) Nature 354, 84 and 81, respectively, and Blake and Litzi-Davis (1992), Bioconjugate Chem 3, 510.

The utility of agents affecting BACE secretase / sheddase function are identified with assays employing the lead compound of interest and testing its effect on A β
10 production either in the absence or the presence of β APP. For example, a method for identifying an agent that can alter the ability of BACE secretase / sheddase to associate with and process a known substrate might comprise the following:

15 in a reaction mixture, allowing BACE secretase / sheddase to bind to a known substrate of BACE secretase / sheddase in the presence of an agent to be tested; and

20 measuring the production of BACE C-terminal cleavage products, shed BACE or A β in the presence of the agent to be tested, and comparing same under conditions when the agent to be tested is absent from the reaction mixture.

The method relies on the activity of BACE secretase / sheddase in the presence of at least one direct substrate for this enzyme, namely BACE or BACE fragments, or in
25 the presence of the indirect substrate β APP. (β APP is considered an indirect substrate for BACE secretase / sheddase for the following reason : BACE secretase / sheddase reacts with BACE or BACE fragments and, if either one of these substrates is suitably modified, it can then react with β APP to generate the amyloidogenic A β peptide.)

Useful agents are typically those that bind to and modulate BACE secretase /
sheddase function, such as those that inactivate either enzyme and prevent the
formation of A β . Preferred agents are receptor-specific and do not cross react with
other neural or lymphoid cell membrane proteins. Useful agents may be found within
5 numerous chemical classes, though typically they are organic compounds and
preferably, small organic compounds. Small organic compounds have a molecular
weight of more than 150 yet less than about 4,500, preferably less than about 1500,
more preferably, less than about 500. Exemplary classes include peptides,
saccharides, steroids, heterocyclics, polycyclics, substituted aromatic compounds, and
10 the like.

Selected agents may be modified to enhance efficacy, stability, pharmaceutical
compatibility, and the like. Structural identification of an agent may be used to
identify, generate, or screen additional agents. For example, where peptide agents are
15 identified, they may be modified in a variety of ways as described above, e.g. to
enhance their proteolytic stability. Other methods of stabilization may include
encapsulation, for example, in liposomes, etc. The subject binding agents are prepared
in any convenient way known to those skilled in the art.

20 For therapeutic uses, agents affecting BACE secretase / sheddase function
may be administered by any convenient way. Small organics are preferably
administered orally; other compositions and agents are preferably administered
parenterally, conveniently in a pharmaceutically or physiologically acceptable carrier,
e.g., phosphate buffered saline, or the like. Typically, the compositions are added to a
25 retained physiological fluid such as blood or synovial fluid. For CNS administration, a
variety of techniques are available for promoting transfer of the therapeutic across the
blood-brain barrier including disruption by surgery or injection, drugs which
transiently open adhesion contact between CNS vasculature endothelial cells, and
compounds which facilitate translocation through such cells.

As examples, many such therapeutics are amenable to direct injection or infusion, topical, intratracheal/nasal administration e.g. through aerosol, intraocularly, or within/on implants (such as collagen, osmotic pumps, grafts comprising appropriately transformed cells, etc.). A particularly useful application involves
5 coating, imbedding or derivatizing fibers, such as collagen fibers, protein polymers, etc. with therapeutic peptides. Other useful approaches are described in Otto et al. (1989) J Neuroscience Research 22, 83-91 and Otto and Unsicker (1990) J Neuroscience 10, 1912-1921. Generally, the amount administered will be empirically determined, typically in the range of about 10 to 1000 $\mu\text{g/kg}$ of the recipient. For
10 peptide agents, the concentration will generally be in the range of about 50 to 500 $\mu\text{g/ml}$ in the dose administered. Other additives may be included, such as stabilizers, bactericides, etc. These additives will be present in conventional amounts.

For antisense applications where the inhibition of expression is indicated,
15 especially useful oligonucleotides are between about 10 and 30 nucleotides in length and include sequences surrounding the disclosed ATG start site, especially the oligonucleotides defined by the disclosed sequence beginning about 5 nucleotides before the start site and ending about 10 nucleotides after the disclosed start site.

20 The compositions and methods disclosed herein may be used to effect gene therapy. See, e.g. Zhu et al. (1993) Science 261, 209-211; Guiterrez et al. (1992) Lancet 339, 715-721. For example, cells are transfected with sequences encoding a peptide or ribozyme operably linked to gene regulatory sequences capable of effecting altered BACE secretase / sheddase expression, regulation, or function. To modulate
25 BACE secretase / sheddase expression, regulation, or function, target cells may be transfected with complementary antisense polynucleotides. For gene therapy involving the grafting/implanting/transfusion of transfected cells, administration will depend on a number of variables that are ascertained empirically. For example, the number of cells will vary depending on the stability of the transferred cells. Transfer

media is typically a buffered saline solution or other pharmacologically acceptable solution. Similarly the amount of other administered compositions (e.g. transfected nucleic acid, protein, etc.) will depend on the manner of administration, purpose of the therapy, and the like.

5

The present invention further comprises a method for determining whether an individual is at risk of developing a neurodegenerative disorder that is characterized by the generation of A β protein, such as Alzheimer's Disease. Generally, this method involves extracting a sample tissue or fluid (such as cerebrospinal fluid or blood platelets) from the individual and determining whether the level of BACE C-terminal cleavage products, shed BACE or A β protein in the tissue or fluid sample is higher than the level in a tissue or fluid sample from a healthy subject, as an indication that the individual is at risk for the neurodegenerative disorder. The method relies on the activity of BACE secretase / sheddase in the presence of at least one direct substrate for this enzyme, namely BACE or BACE fragments, or in the presence of the indirect substract β APP. (β APP is considered an indirect substrate for BACE secretase / sheddase for the following reason : BACE secretase / sheddase reacts with BACE or BACE fragments and, if either one of these substrates is suitably modified, it can then react with β APP to generate the amyloidogenic A β peptide.)

20

The present additionally comprises a kit that is suitable for such diagnoses. For example, a compartmentalized kit in accordance with the present invention includes any kit in which reagents are contained in separate containers or vessels. Such containers include small glass containers, plastic containers or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample (fluid or tissue) and containers with

25

BACE secretase / sheddase and at least one substrate of this enzyme, namely, BACE or BACE fragments, or the indirect substrate β APP.

5 MATERIALS AND METHODS

Mouse BACE and its mutants- Full length mouse BACE (mBACE_F) was cloned from AtT20 cells by RT-PCR (Titan One-Tube, Boehringer) using the following nested sense (S) and antisense (AS) oligonucleotides: S1= AAGCCACCACCACCCAGACTTAGG (SEQ ID NO :5); S2= CTCGAGCTATGGCCCCGGCGCTGCGCTG (Xho-I site at 5') (SEQ ID NO :6) and AS1= GAGGGTCCTGAGGTGCTCTGG (SEQ ID NO :7); AS2= CCTCCTCACTTCAGCAGGGAGATG (SEQ ID NO :8). The final product (1519 bp) was then completely sequenced and matched with the published structure (11), then subcloned into the expression vector pcDNA3.1/Zeo (Invitrogen). In order to detect recombinant BACE_F, either a V5 (GKPIPNPLLGLDST (SEQ ID NO :9); [BACE_F]_{V5}) or Flag (DYKDDDDK (SEQ ID NO :10) were added, in phase, by PCR; [BACE_F]_{FG}) epitope to the C-terminal amino acid of the cytosolic tail of mouse BACE. A BACE_F construct was also prepared in pIRES2-EGFP (Invitrogen) in which a FLAG epitope was introduced just after the signal peptide cleavage site (giving the sequence ...GMLPA↓DYKDDDDK-QGTHL...) (SEQ ID NO :11) and a V5 epitope was at the C-terminus of the molecule [BACE_F]_{FG/V5}. Other BACE constructs were also prepared including: (1) an active site D93A mutant singly [BACE_F-D93A]_{FG} or doubly tagged [BACE_F-D93A]_{FG/V5}; (2) a prosegment deletion mutant [BACE_F-Δp]_{FG} in which the signal peptide ending at Ala₁₉ is fused directly to the sequence ...MLPA₁₉↓QG-PRE₄₆TDEE... (SEQ ID NO :12); (3) PC-cleavage site (R₄₂LPR₄₅) mutants [BACE_F-R45A]_{FG} as well as the double tagged [BACE_F-R42A]_{FG/V5} and [BACE_F-R45A]_{FG/V5}; (4) deletion of the prosegment in the active site mutant [BACE_F-Δp-D93A]_{FG}; and (5) cytosolic tail Cys-mutants, including single [BACE_F-C478A]_{FG}, [BACE_F-C482A]_{FG}, [BACE_F-C485A]_{FG}, double [BACE_F-C482,485A]_{FG},

and triple [BACE_F-C478,482,485A]_{FG} mutants. Soluble forms of BACE (BACE_S) were also prepared by deleting the transmembrane domain (TMD) and cytosolic tail (CT), leaving the sequence ...TDEST₄₅₄ (SEQ ID NO :13) followed by a V5 epitope. These constructs included [BACE_S]_{V5}, [BACE_S]_{FG/V5}, [BACE_S-R42A]_{FG/V5} and
5 [BACE_S-R45A]_{FG/V5}.

Transfections and biosynthetic analyses- All transfections were done on 2-4 x 10⁵ HK293 cells using Effectene (Qiagen) and a total of 1-1.5 µg of BACE construct cDNAs subcloned into the vector pIRES2-EGFP. Two days post-transfection the cells
10 were washed and then pulse-incubated for various times with either 200 µCi/ml of [³⁵S]Met; 400 µCi/ml Na₂[³⁵SO₄], [³H]Leu, [³H]Arg, [³H]Ser; or 1 mCi/ml [³H]palmitate (NEN) (20). Pulse-chase experiments with [³⁵S]Met were carried out as previously described (21). Cells were lysed in immunoprecipitation buffer [150 mM NaCl, 50 mM Tris-HCl pH 6.8, 0.5% NP40, 0.5% sodium deoxycholate and a
15 protease inhibitor cocktail (Roche Diagnostics). The lysates and media were then prepared for immunoprecipitations as reported (22). The monoclonal antibodies used were directed against either the FL (Flag-M2; 1:500 dilution; Stratagene) or V5 (1:1000 dilution; Invitrogen) epitopes. Rabbit polyclonal antisera included those directed against aa 1-16 of human Aβ (produced in laboratory, dilution 1:200); anti-β-amyloid, recognizing mostly the C-terminal part of Aβ₄₀ (A8326, dilution 1:200, Sigma); and FCA18, recognizing all peptides starting with the Asp at the N-terminus
20 of Aβ (23). Immunoprecipitates were resolved on SDS-PAGE (either 8% or 14% tricine gels) and autoradiographed (21). All PC inhibitor proteins were cloned in pcDNA3 (Invitrogen), including those of α1-PDX (8); the preprosegments of furin, PC7 (24), PC5 (25), SKI-1 (26,27); and wild type (α2-M) and furin-site mutated (α2-MG-F) α2-macroglobulin (28).
25

In vitro assays and Western blotting- Enzymatically active BACE was obtained from 10-20 fold-concentrated media of HK293 cells transiently transfected with the cDNAs

of [BACE_S]_{FG/V5}, [BACE_S-R42A]_{FG/V5} or [BACE_S-R45A]_{FG/V5}. Beta-secretase activity was evaluated using a 20 aa synthetic peptide spanning the cleavage site (KTEEISEVNL↓DAEFRHDSGY) (SEQ ID NO :14) of βAPP_{sw}. Reactions were carried out using 10-30 μM peptide for 16-18 hrs at 37 °C in 100 μl of 50 mM NaOAc (pH 4.5), plus 10 μg/ml of leupeptin to inhibit low levels of a non-β-secretase proteolytic activity. The digestion products, separated and quantitated via RP-HPLC (TFA/acetonitrile gradient) on a C-18 column (Vydak), were identified using MALDI-TOF mass spectroscopy (Voyager/Perkin Elmer). ProBACE incubations were carried out in the same fashion using either [proBACE_S]_{FG/V5} or [proBACE_S-R42A]_{FG/V5} purified on an anti-FL M1 agarose affinity column (Sigma) according to the manufacturer's instructions. Incubations with the peptide comprising the entire prosegment of mBACE (THLGIRLPLRSGLAGPPLGLRLPR (SEQ ID NO :15), 10-30 μM final concentration) were carried out as for β-secretase activity measurements.

PC-mediated digestions entailed preincubating the various BACE constructs for up to 4 h in 50 μl of 50 mM Tris-Oac (pH 7.0) plus 2 mM CaCl₂ (and 0.1 % Triton X-100 (v/v), for Western blot analysis of BACE prosegment removal) in the presence of media from BSC40 infected with vaccinia virus recombinants of human furin, PACE4, and mouse PC5-A (29), as well as rat PC7 (30). The activities of the different PC preparations were estimated according to the initial hydrolysis rates of the pentapeptide fluorogenic substrate pERTKR-MCA (SEQ ID NO :16) (29,30). PC activity-inhibited controls comprised 4h incubations in the presence of 1 μM of the corresponding purified prosegments of PCs (24,25). Digestions of the PC cleavage site-spanning peptide (LGLRLPR↓ETDEESEEPGRRG) (SEQ ID NO :17) by PCs were carried out as above for the BACE preincubations (except in 100 μL), whereas digestions by BACE were as for β-secretase activity at pH 4.5 or 6.5. Digestion products were again quantitated by RP-HPLC and MALDI-TOF mass spectroscopic analysis.

Western blot analyses of the reaction products were carried out following 10% SDS-PAGE using either the FG (1:1000 dilution) or V5-HRP (1:5000 dilution) monoclonal antibodies (Stratagene). The secondary antibody for FG consisted of anti-mouse HRP-coupled IgGs (Boehringer Mannheim).

5

Generation of antiserum to human BACE – Monospecific polyclonal rabbit antiserum that recognizes the peptide sequence ELARPDDSLEPFFDSL VK (SEQ ID NO :18) in human (NCBI Protein NP_036236) (SEQ ID NO :19) and mouse BACE (NCBI P56818) (SEQ ID NO :20) was generated by Research Genetics. The initial immunogen was a 393 long fragment of human BACE (from MVDNLRG to OTDESTL) expressed as a C-terminal His-tagged protein in a pET-24B vector in bacteria BL21(DE3)pLysS (Stratagene).

10

15 *Radiosequencing of 15, 11, 34 and 6 kDa BACE fragments* – The SDS-PAGE extracted fragments were treated to remove excess salts and SDS and applied on a PVDF membrane into an ABI Procise 477 cLC sequencer. The standard program was modified for radioactive sequencing, whereby the effluent was directed to a fraction collector. Typically, 20-25 sequencer cycles were collected for each run. Subsequently, the radioactive counts were quantified on a Beckman sequencer.

20

RESULTS

Biosynthesis and processing of BACE - In order to characterize the biosynthetic pathway of BACE and its post-translational modifications, the enzyme from the mouse corticotroph cell line AtT20 was cloned. The resultant, fully sequenced 1519 bp product corresponded to the published mouse sequence (11). In order to detect membrane bound proBACE or BACE, the V5 epitope at the C-terminus of the cytosolic tail was used. Alternatively, the N-terminal Flag epitope (FG) immediately following the signal peptidase cleavage site to specifically detect

25

30

proBACE was employed. This doubly-tagged, full-length (F) protein [BACE_F]_{FG/V5} was co-expressed in human kidney epithelial cells (HK293) either with a control (CTL) [brain derived neurotrophic factor (BDNF)] or α 1-PDX cDNA. Two days after transfection, the cells were pulse-labeled with [³⁵S]Met for 15 min (P15). They were then chased for 1h or 2h in the presence or absence of the fungal metabolite brefeldin A (BFA), which promotes fusion of the *cis*, *medial* and *trans* Golgi (but not the TGN) with the ER (31). Cell extracts were immunoprecipitated with either FG or V5 monoclonal antibodies and analysed by SDS-PAGE (Fig. 1). In the absence of BFA and α 1-PDX at P15 (Fig. 1A), the FG epitope reveals a 66 kDa proBACE form that is gradually transformed first into a 64 kDa (C1h) and then into a minor 72 kDa (C2h) proBACE form. Whereas the 72 kDa form is not apparent in the presence of BFA (the major band is visible at 63 kDa), it is greatly enriched in the presence of α 1-PDX (Fig. 1B). Treatment with endoglycosidases revealed that the 63 and 64 kDa proBACE forms are sensitive to both endoH and endoF, whereas the 72 kDa form is sensitive only to endoF (*not shown*). These data suggest that the 63 and 64 kDa bands represent immature (likely ER-resident), N-glycosylated proBACE whereas the 72 kDa form represents mature proBACE. Only in the presence of α 1-PDX does proBACE immunoreactivity accumulate in the Golgi apparatus. In immunoprecipitation experiments employing the V5 epitope, the 2h-chase period revealed mainly a 68 kDa band (Fig. 1C). In the presence of α 1-PDX (Fig. 1D), an accumulation of a 72 kDa protein reminiscent of proBACE (Fig. 1C) was observed.

N-terminal radiosequencing (26,30) was carried out on SDS-PAGE-purified immunoprecipitates. The C-terminally flagged 72 kDa [proBACE_F]_{FG}, labeled with [³H]Leu and produced in the presence of α 1-PDX, had a Leu_{3,7,9,13} sequence (*not shown*). This is consistent with the protein starting at Thr₂₂ (AQG₂₁↓T₂₂HLGIRLPLRSGL) (SEQ ID NO:21) which is just after the signal peptidase cleavage site (8,9). The corresponding 68 kDa protein, labeled with [³H]Ser, revealed a Ser₆ signal (*not shown*), compatible with the protein being mature BACE

obtained following removal of the prosegment (aa 22-45) at the RLPR₄₅↓E₄₆TDEESEE sequence (SEQ ID NO :22).

In order to determine whether a proprotein convertase(s) could carry out the processing of proBACE to BACE, the doubly-tagged [BACE_F]_{FG/V5} was transiently co-expressed in HK293 cells with an array of PC-inhibitors including: α1-PDX (8,21); the pre-prosegments of furin, PC7 (24), PC5 (25), and SKI-1 (27); and the wild type (α2M) and furin-inhibiting mutant (α2M-F) forms of α2-macroglobulin (28). In addition, mutant forms of BACE were prepared in which the PC-consensus cleavage site Arg residues in the prosegment were replaced by Ala at positions 42 or 45 (R42A or R45A, respectively). The transfected cells were pulse-labeled for 20 min with [³⁵S]Met and then chased for 90 min without label. Following immunoprecipitation of the cell lysates with a FG antibody, the material was analysed by SDS-PAGE. When BACE was co-expressed with either α1-PDX, proFur, proPC5 or α2M-F, the quantity of the 72 kDa proBACE (pBACE_G, Golgi form) was elevated (Fig. 2A). Similar results were seen for both the R42A or R45A prosegment cleavage site mutants. In contrast, the 72 kDa proBACE was barely detectable in the control, proPC7, proSKI-1 or α2M co-expressions. Parallel control experiments (*not shown*) verified that the prosegments of PC7 (24) and SKI-1 (27) were able to inhibit processing of appropriate substrates by their cognate enzymes. These data strongly support the hypothesis that a PC-like enzyme may be involved in the processing of proBACE into BACE. The prosegment results implicate furin and PC5 as likely PC candidates, whereas PC7 and SKI-1 appear unlikely to mediate this process. The finding that the Arg residues at the predicted canonical R₄₂-X-X-R₄₅↓ site are essential for proBACE processing is also consistent with the reported cleavage specificities of furin and PC5 (7).

In order to better define the region of the Golgi where proBACE processing occurs, [BACE_F]_{FG/V5} was co-expressed in HK293 cells with either furin or α1-PDX

and then labeled the cells for 2h with $\text{Na}_2[^{35}\text{SO}_4]$. SDS-PAGE analyses of the FG or V5-immunoprecipitates are shown in Fig. 2B. Using the FG-antibody, it was observed that proBACE is weakly sulfated (CTL). In the presence of $\alpha 1$ -PDX, the intensity of the 72 kDa $[^{35}\text{SO}_4]$ -proBACE (pBACE_G) was greatly enhanced. The V5-immunoprecipitates clearly demonstrated that BACE is sulfated, and further revealed that furin digestion appears to lower the average apparent mass of sulfated BACE from 72 (pBACE_G) to 68 kDa (BACE_G). Finally, the data suggest that processing of proBACE by a PC-like enzyme into BACE occurs at the TGN or in a subsequent compartment. Not only are sulfotransferases located in this region of the secretory pathway (32,33) but, with the exception of PC5-B (34), all other PCs become active only at or beyond the TGN (7), which is also a major site where $\alpha 1$ -PDX acts (21).

The next set of experiments were devised to determine whether PCs could process proBACE *in vitro*. In preliminary work, testing was conducted to find which of the PCs expected to be active in the constitutive secretory pathway could correctly cleave a peptide (proBACE 38-54) spanning the N-terminal furin-consensus site. The best processing rates were observed with furin and PC5 (*not shown*), followed distantly by PACE4. PC7 could barely cleave this sequence, even when a 10-fold excess (as assessed by pERTKR-MCA hydrolysis) of activity was employed. At the same time, no detectable cleavage of this peptide was observed by either crude or partially purified soluble BACE [BACE_S]_{V5} (*not shown*), lending further support to the view that the BACE does not autocatalytically remove its own propeptide. The PC-mediated processing of a doubly tagged soluble (S) form of proBACE [BACE_S]_{FG/V5} expressed in HK293 cells was examined next. Western blots of the secreted enzyme probed by the FG antibody revealed that some of the enzyme was still in the form of proBACE_S. The concentrated medium of HK293 cells was thus used as a source of proBACE_S. Aliquots of this medium (equalized by their V5 immunoreactivities) were incubated with equivalent hydrolytic activities (estimated using the fluorogenic substrate pERTKR-MCA) of partially purified furin, PC5,

PACE4 and PC7 for 1-4 hours. The digestion products were then run on SDS-PAGE and revealed by western blotting using either the FG or V5 antibodies. The data demonstrated that furin could completely process proBACE into BACE within 2h, which was superior to the abilities of PC5 and PACE4 to carry out this cleavage (Fig. 3). In contrast, PC7 is barely, if at all, able to perform this reaction. As further confirmation of the identity of the enzyme(s) carrying out this conversion, we treated the 4h proBACE digestion reaction with 1 μ M purified PC prosegments (pPCs) produced in bacteria as previously reported (24). Correspondingly, the pPCs of furin, PC5 and PACE4 inhibited proBACE processing. Finally, analysis of the R45A mutant (Fig. 3, right-hand side) of proBACE_s with both the V5 and FG epitopes indicated that none of the PCs tested could cleave this form, consistent with processing occurring at Arg₄₅. Similar results were obtained using the R42A mutant (*not shown*). Finally, coexpression of [BACE_F]_{FG} in furin-deficient LoVo cells (35) with each of the above PCs or with the yeast PC homologue kexin revealed that furin, kexin and less so PC5 could best mediate efficient intracellular processing of proBACE into BACE (*not shown*).

Post-translational modifications of BACE and their effects on β -secretase activity

- In order to investigate the functions of the prosegment and the transmembrane/cytosolic tail of BACE, a series of mutants singly tagged at the C-terminus with a FG or V5 epitope were prepared. The first construct was a truncated form of full length BACE in which the prosegment was removed (BACE- Δ p). Ala mutants of three Cys residues located within the cytosolic tail of BACE_F that are potential Cys-linked palmitoylation sites (36) were also engineered. Accordingly, three single (Cys 478, 482 and 485) were made, as well as double (C482,485A) and triple (C478,482,485A) mutants. As previously, transiently transfected HK293 cells were pulse-labeled for 20 min with [³⁵S]Met followed by a chase of either 1 or 2h. SDS-PAGE analysis of the FG-immunoprecipitated products (Fig. 4A) revealed that, in contrast to the wild-type [BACE_F]_{FG}, the truncated [BACE- Δ p]_{FG} remains mostly in

the ER, with only trace amounts reaching the TGN. This mutant also demonstrated a high level of endoH sensitivity and a very low level of sulfation (*not shown*). However, N-terminal sequencing of [³H]Arg-labeled [BACE-Δp]_{FG} revealed a major sequence with an Arg₅, indicating that the signal peptide of this mutant was poorly
5 cleaved (*not shown*). These data suggest that the majority of BACE-Δp remains in the ER, and only a small fraction reaches the TGN and is sulfated. This was further corroborated by immunocytochemical evidence showing that the majority of BACE-Δp immunoreactivity was concentrated in the ER (*not shown*). In contrast, BACE_S passes rapidly through the secretory pathway, as evidenced by its accumulation in the
10 medium after 1h of chase (Fig. 4A) and the relatively low amounts of proBACE_S in the ER (endoH-sensitive, lower band in cells; *not shown*) after either 1 or 2h of chase. By transfecting [BACE_S]_{FG} into HK293 cells and then labelling for 2h with Na₂[³⁵SO₄], the intramolecular site(s) at which sulfation of BACE occurs could be examined. Equal aliquots of the FG-immunoprecipitated media were digested with
15 endoH, endoF or aryl sulfatase (ASase). Only endoF removed the [³⁵SO₄]-label (Fig. 4B), demonstrating that sulfation occurred on one or more mature N-glycosylation sites (32), but not on tyrosine residues (33).

Fig. 4C shows the results of SDS-PAGE analysis of FG-immunoreactive
20 proteins following a 2h labeling with [³H]palmitate of HK293 cells transiently overexpressing either BACE_F, its cytosolic tail Cys-mutants, BACE-Δp or BACE_S. Both BACE_F (68 kDa) and the ER-concentrated preBACE-Δp (64 kDa) were palmitoylated. When each of the three Cys residues was individually mutated, a significant decrease in the degree of palmitoylation (*not shown*) was observed. The
25 double (C482,485A) mutant had ≤ 30% as much palmitoylation as the wild type BACE_F, whereas the triple mutant C478,482,485A was barely palmitoylated. The observation that each of the mutants was expressed to similar degrees based on their FG-immunoprecipitated reactivities following a 2h pulse-labeling with [³⁵S]Met was verified (*not shown*). These data demonstrate that palmitoylation can occur at all three

of the Cys (478, 482 and 485) residues within the cytosolic tail of BACE_F. Predictably, soluble BACE_S was not palmitoylated. The fact that the 64 kDa preBACE-Δp was palmitoylated, as opposed to the mature 68 kDa BACE_F, suggests that this type of post-translational modification can begin at the level of the ER (36).

5

The enzymatic activity of [BACE_F]_{FG} was first tested in HK293 cells transfected with βAPP_{sw} cDNA. Following a 3h pulse-labeling with [³⁵S]Met (Fig. 5), the cells were exposed to either BFA, bafilomycin (an inhibitor of vesicular acidification) (37) or a 20°C incubation (which prevents most secretory proteins from leaving the TGN) (38). Fig. 5A shows that BFA and the 20°C incubation prevented FG-immunoprecipitated 66 kDa proBACE from escaping the ER and becoming either the 72 kDa proBACE or mature, endoH-resistant BACE (*not shown*), whereas bafilomycin exerted a retarding effect in the ER (compared to untreated cells). As shown in Fig. 5B, co-expression of wild-type BACE_F and βAPP_{sw} lead to the production of a membrane-bound ~10 kDa intracellular product (C99) that was detected by a polyclonal antibody raised against the N-terminal 16 aa of Aβ. This band was also observed using the Aβ N-terminal-specific antibody FCA18 (23), confirming that this cleavage product began with the correct N-terminus of Aβ (starting at the β-secretase cleavage site sequence D₆₅₃AEFRHDS...) (SEQ ID NO :23) and likely ended at the C-terminus of βAPP, as reported previously (11,12). Unexpectedly, regardless of the relative levels of BACE and proBACE, βAPP_{sw} was well processed in the ER. In other pulse and pulse-chase experiments it was observed that the maximal amount of C99 product was generated by BACE_F after a 20 min pulse, consistent with production of C99 in an early secretory compartment, likely to be the ER. Finally, tests were conducted to determine whether BACE_F may be transformed into a soluble shed-form. As shown in Fig. 5C, a small amount of ~6 kDa form of FG-labeled BACE_F but not FG-labeled BACE_S could indeed be detected. This suggests that shedding of membrane-bound BACE_F can occur to a small extent.

In the next set of experiments (Fig. 6), wild-type BACE and selected BACE mutants were co-expressed with β APP_{sw}. As shown in Fig. 6A, C99 production was evident in cells co-expressing wild type BACE_F and β APP_{sw} following pulse-labeling for 4h with [³⁵S]Met. Unexpectedly, the same band, although less intense, was also
5 obtained with the mutants [BACE_F-R45A] and BACE_F- Δ p (Fig. 6A), as well as with the [BACE_F-R42A], [BACE_F-C482,485A] and [BACE_F-C478,482,485A] mutants (*not shown*), indicating that all of these isoforms have at least some activity. The absence of C99 production by the active site mutant [BACE_F-D93A] confirms that these activities actually correspond to BACE and its mutant forms (Fig. 6A). Notably,
10 the soluble form of BACE_S produced much less C99 compared to any of the other active forms analysed, even though similar amounts of immunoreactive BACE were expressed (*not shown*).

Next, the secreted β APP cleavage products were analysed using a polyclonal
15 antibody developed against A β ₄₀ as well as the antibody FCA3340 (*not shown*) recognizing the C-terminus of A β ₄₀ (23). Both antisera recognize A β ₄₀ (generated by the β - and γ -secretases) and A β _{x-40} (e.g., A β ₁₁₋₄₀ generated by overexpressed β -secretase; see ref. 11). Amazingly, BACE_S and, to a lesser extent, BACE- Δ p were by far the forms of β -secretase that ultimately lead to the formation of the most
20 amyloidogenic A β peptide (Fig. 6B). Overexpression of either BACE_F or BACE_{R45A} (as well as the Cys-mutants [BACE_F-C482,485A] and [BACE_F-C478,482,485A], *not shown*) resulted in an elevation of the level of the non-amyloidogenic A β _{x-40} product (possibly A β ₁₁₋₄₀, see ref. 11) with no significant change in that of A β ₄₀. Again, as expected, [BACE_F-D93A] was inactive.

25 When the levels of secreted APP_S generated by α -secretase were analysed using the same 1-16 A β antibody, an inverse relationship between the levels of C99 and those of secreted APP_S was noticed. BACE_F, [BACE_F-R45A], BACE_F- Δ p

generated higher amounts of the non-amyloidogenic C99 and A β_{x-40} along with lower levels of secreted APPs, whereas control cells or cells overexpressing the inactive [BACE_F-D93A] mutant secreted much more pronounced APP_s levels (Fig. 6C). These data provide evidence that the APP_s measured with the 1-16 A β antibody is probably APP_s α resulting from cleavage of β APP by α -secretase either at the TGN or at the cell surface (5,39). In comparison, other data (Fig. 5) showed that overexpressed BACE or its mutants process β APP_{sw} in an earlier compartment such as the ER and thus precede the action of α -secretase. Interestingly, overexpression of wild-type mouse PS1 (*not shown*) resulted in higher levels of either cellular C99 or secreted A β and APP_s products, suggesting that in HK293 cells wild-type PS1 increases the exposure of β APP_{sw} to its cognate β -, α - and γ -secretases, yet does not seem to specifically increase the γ -secretase activity (40).

In order to further examine the possibility that proBACE has β -secretase activity, digestion analyses of a synthetic peptide substrate (KTEEISEVNL↓DAEFRHDSGY) (SEQ ID NO :14) encompassing the β APP_{sw} β -secretase cleavage site were carried out *in vitro* using concentrated media of HK293 cells that overexpressed BACE_s. In four separate experiments, pre-incubation of BACE_s-containing media with furin produced a significant increase, $50 \pm 3\%$, in the level of BACE activity. In contrast, no activation of the [BACE_s-R45A] mutant by furin was found. Concomitant Western blotting (Fig. 3) confirmed that furin had removed the FG epitope from the prosegment of the wild-type but not the [BACE_s-R45A] mutant. When proBACE was affinity-purified using an anti-FLAG M1-agarose column, the resulting material had no detectable activity unless first pre-incubated with furin. These data imply that removal of the prosegment from proBACE significantly enhances the activity of this enzyme. Thus, tests were conducted to see whether a synthetic peptide representing the full-length prosegment (proBACE 22-45) would function as an inhibitor. When pre-incubated with active

BACE, 20 μ M of this peptide resulted in only a ~20% inhibition of the Swedish peptide substrate (at 10 μ M) cleavage.

C-terminal processing of BACE - In order to further characterize the nature of apparent C-terminal cleaved BACE fragments (Fig. 5C), the analysis of [BACE_F]_{FG} fragments immunoprecipitated with antiserum to Flag from HK293 cells were repeated. In addition to the 6 kDa fragment noted in Fig. 5C, fragments of 34, 15, and 11 kDa are apparent (Fig. 7). Significantly, the 34 and 15 kDa bands disappear under non-reducing conditions indicating that they are disulfide linked. In addition, the intensity of the 11 and 6 kDa bands appear to diminish. It was expected that some of these BACE fragments would be disulfide linked, since it is known that the six Cys residues in the ectodomain form three intramolecular disulfide linkages (Cys²¹⁶-Cys⁴²⁰, Cys²⁷⁸-Cys⁴⁴³, Cys³³⁰-Cys³⁸⁰) (41). The 34, 15, 11 and 6 kDa BACE fragments are also apparent when [BACE_F]_{FG} is expressed in Neuro 2a cells (Fig. 8). The relative levels of the 11kDa fragment compared to the other cleaved fragments of BACE appear lower in Neuro 2a compared to HK293 cells. In any case, the sites of ectodomain cleavage are apparently the same in the two cell types. Clearly, γ -secretase activity is not responsible for the formation of the 34, 15 and 11 kDa BACE fragments, since under conditions in which a γ -secretase substrate-based difluoro ketone inhibitor (46) completely inhibits A β formation (Panels C and D) and elevates cellular C99 levels (Panel B), the levels of BACE fragments are largely unchanged (Panel A). The significance of an apparent reduction in the level of the 6 kDa BACE fragment is unknown.

With an antiserum that recognizes a region of BACE (amino acids 186-203) that is N-terminal to both any disulfide-linked cysteines and the observed 15, 11, and 6 kDa apparent C-terminal fragments (based on size), the presence of BACE shed from BACE_F into the media could be detected (Fig. 9). Shed BACE appears to be smaller than BACE_S (truncated at Thr₄₅₄ at the lumen/extracellular border of the TM

region) secreted into the media. It is noteworthy that shed BACE is larger than the major cellular form of BACE (pBACE_{ER}) due to post-translational modification. In cells, the 34 and 15 kDa truncated forms of BACE are immunoprecipitated with this N-terminal antiserum as observed with the antiserum to the C-terminal flag. This result is consistent with the observation that the 34 and 15 kDa fragments of BACE are disulfide-linked (Fig. 7).

Cleavage site determination - The location of the sites of proteolytic cleavage to generate the 34, 15, 11 and 6 kDa fragments of BACE were determined by N-terminal radiosequencing of ³⁵S-Met and ³H-Phenylalanine labeled SDS-PAGE purified material. N-terminal sequence analysis of the 15 kDa BACE fragment indicated the presence of methione in positions 15 and 20, and phenylalanine in position 4 (Fig. 10). Therefore, the 15kDa C-terminal BACE fragment starts at Cys₃₈₀ that likely results from proteolytic cleavage of BACE after Asp₃₇₉. The 34 kDa radiosequence indicates the presence of phenylalanine in position 15, which is consistent with this fragment being the N-terminus of BACE cleaved at Asp₃₇₉ (SQDD↓) (SEQ ID NO :24) with its prosegment removed by furin cleavage.

N-terminal sequence analysis of the 11 kDa fragment (Fig. 11) indicated the presence of phenylalanine in position 8 and the absence of methione. The sequence and the size of the fragment are consistent with cleavage of BACE after Asp₄₀₇ (VVFD↓) (SEQ ID NO :25). Interestingly, sequence analysis of the 6 kDa fragment indicated the presence of phenylalanine in position 8. Therefore, this fragment results from C-terminal cleavage of the 11 kDa fragment perhaps at more C-terminal Asp, likely after Asp₄₅₁ (PQTD↓) (SEQ ID NO :26), in the BACE ectodomain.

DISCUSSION

The discovery of a unique type-I membrane-bound BACE has provided a new perspective in the understanding of β -secretases (11-15). Recent data on the tissue expression of BACE in mouse and human brain (10) indicate that it co-localizes with β APP and ADAM10 in the cortex and hippocampus of adult mice and in the cortex of human presenile patients. Furthermore, the distribution of either BACE2 or ADAM17 were not compatible with them being candidate brain β - or α -secretases, respectively.

The focus of the present work was on BACE, the more plausible β -secretase, in order to define some of its molecular and cellular trafficking properties. It was first shown that in HK293 cells BACE is synthesized as proBACE in the ER and then moves to the TGN where it rapidly loses its prosegment due to cleavage by an α 1-PDX inhabitable convertase(s). Next, it was shown that, aside from α 1-PDX and the furin-site mutated α 2-macroglobulin, other inhibitors such as the preprosegments of furin and PC5 can also inhibit proBACE processing. This cleavage occurs at the sequence $R_{42}LPR_{45}\downarrow$ of proBACE sulfated at one or more of its carbohydrate moieties. Since sulfation of sugars occurs in the TGN (32) and PCs, except perhaps PC5-B (34), are active only in this compartment or beyond, these were taken as indications that processing of proBACE to BACE occurs in the TGN or in post TGN-vesicles. *In vitro* digestion of proBACE (Fig. 3) and *ex vivo* co-expression of BACE and the PCs in the furin-negative LoVo cells (*not shown*) demonstrated that zymogen processing was best performed by furin, and less so by PC5.

Next, the data generated showed that full length BACE_F is palmitoylated at the cytosolic tail cysteines 478, 482 and 485 and that a soluble form of BACE_S is not (Fig. 4C). Interestingly, BACE_S seems to be rapidly secreted from and does not accumulate within the cell, suggesting that the cytosolic segment of BACE_F must contain determinants that control cellular trafficking rates and destination. One such

element could be Cys-palmitoylation, since pulse-chase experiments demonstrated that the triple mutation C478,482,485A results in slowing down exit of proBACE from the ER (*not shown*). However, immunocytochemical analysis of the localization of [BACE_F]_{FG} and [BACE_F-C478,482,485A]_{FG} failed to reveal gross differences in their cellular distribution (*not shown*). Although the role of palmitoylation of BACE, which begins in the ER, remains to be elucidated, this modification may provide a second anchor to the plasma membrane, thus directing the protein to discrete membrane microdomains or remodeling the structure of its cytoplasmic region (36).

Mutagenizing either of the arginines found to be critical for the prosegment removal, i.e., R42A or R45A, did not result in significant alteration of the trafficking rate of proBACE to the TGN, as estimated by pulse-chase (Fig. 2A) and sulfation rate analyses. At around the same time as the present results were coming to light, two *in press* reports on the biosynthesis of BACE reported similar observations (41,42). In the report by Capell *et al.* regarding the prosegment removal of human BACE (42), their data, like the present results, also revealed that such processing occurs in the TGN and that BACE_S trafficks more rapidly than BACE_F towards the TGN. The data differ from theirs, which suggests that the R45A mutant of human BACE does not exit the ER. The triplicate pulse-chase data (Fig. 2A) clearly demonstrate that the exit of both proBACE_F and proBACE_F-R45A (or R42A) to the TGN is slow but does in fact occur to a similar extent for both forms.

An interesting observation was made when the rate of exit of proBACE from the ER was analysed at 20°C, a temperature which normally blocks the budding of TGN vesicles, but which should not prevent movement from the ER to the TGN (38). Amazingly, at 20°C proBACE cannot exit the ER, as is the case with BFA and, much less so, bafilomycin treatments (Fig. 5A). This is reminiscent of the observation that $\alpha\beta$ integrins do not exit the ER at 20°C because of their inability to heterodimerize (43). Whether this means that BACE is part of a larger complex, such as the one

involving presenilins/ γ -secretase (44), is not yet clear. It was previously reported that the production of $A\beta_{40}$ and $A\beta_{42}$ was abrogated at 20°C (17). The present data show that proBACE can process βAPP_{sw} into C99 in the ER (Fig. 5B), suggesting that γ -secretase activity could be the limiting factor at 20°C. Even though the holoenzymes BACE and proBACE (*not shown*) exhibit an *in vitro* pH optimum of 4.5 for cleavage of synthetic peptides mimicking the β -site (11,12,15), the present data is strongly suggestive of the presence of active BACE within the neutral pH environment of the ER (Fig. 5B). The *in vitro* data further showed that removal of the prosegment by furin maximizes the activity of BACE. The combined observations that the active-site mutant [BACE_F-D93A] can lose its prosegment (*not shown*), that BACE did not cleave the PC-cleavage site spanning peptide (aa 39-58 of BACE), and that PCs such as furin and PC5 can remove the prosegment of BACE *in vitro* and *ex vivo* support the notion that BACE does not autoactivate, but likely requires a furin-like enzyme for zymogen activation. Alternatively, the possibility that there are other enzymes or proteins that can interact with proBACE and activate it by cleavage or dislocation of its prosegment cannot be ruled out. Indeed, experiments using affinity-purified BACE indicated that furin-treated BACE is much more active than proBACE. The finding that the BACE zymogen is apparently active is reminiscent of observations regarding the processing of the relatively inactive prorenin to renin by PC5 (45). Modeling of mouse proBACE based on the structure of a close homologue human proGastricsin suggested that the prosegment acts as a flap covering the active site of BACE and that the furin-processing site R₄₂-X-X-R₄₅↓ is quite accessible to cleavage (*not shown*).

In an effort to define the importance of cellular trafficking on the production of C99 and $A\beta$, the ability of various engineered forms of BACE to process βAPP_{sw} and ultimately to generate amyloidogenic peptides was compared. Surprisingly, overexpression of the soluble form of BACE_s results in a very significant increase in the levels of secreted $A\beta$ (Fig. 6B). This experiment, which was repeated 4 times, suggests that the rapid trafficking of the soluble form through the TGN and at the cell

surface may favor the production of C99 in a microcompartment close to where γ -secretase is active. An exciting extension of this model would be that the amyloidogenic potential of BACE is enhanced by BACE C-terminal processing by BACE secretase / sheddase. In both HK293 and Neuro2a cells 34, 15, 11 and 6 kDa BACE fragments (Figs. 7 and 8) and BACE shed into the media (Fig. 9) as the result of BACE secretase / sheddase activity were detected. Finally, overexpression of the active site mutant [BACE_F-D93A] in N2a cells stably overexpressing β APP_{sw} (17) did not affect the generation of either C99 or A β by endogenous secretases (*not shown*), suggesting that this mutant cannot act as a dominant negative, as was the case for the active site mutant of the candidate α -secretase ADAM10 (5).

Thus, the results reported above reveal that BACE can process β APP_{sw} in the ER and that furin or PC5 process the zymogen in the TGN, possibly in order to maximize its activity in acidic cellular compartments. BACE undergoes a number of other post translational modifications such as carbohydrate sulfation and cytosolic tail Cys-palmitoylation which may finely regulate its rate of trafficking and cellular destination(s). The *in vivo* physiological function of BACE remains to be elucidated as well as the possibility that this enzyme may be part of a larger complex with other proteins, including the other secretases involved in the processing of β APP.

20

BACE Secretase / Sheddase Activity - In addition to the data reported above, a novel proteolytic activity that cleaves the ectodomain (juxtamembrane region on the lumen / extracellular side) of BACE after Asp₃₇₉ (SQDD↓) (SEQ ID NO :24) and Asp₄₀₇ (VVFD↓) (SEQ ID NO :25), and likely after Asp₄₅₁(PQTD↓) (SEQ ID NO :26) has been identified (Figs. 10 and 11). This activity has been identified as BACE secretase / sheddase. The shed form of BACE (Fig.9) most likely results from cleavage after Asp₄₅₁(PQTD↓), since it is the only juxtamembrane Asp C-terminal to Cys₄₄₃ that is reported to be linked via a disulfide to Cys₂₇₈ (41). The data indicate that

25

the 15 kDa Asp₃₇₉ cleavage product, and to some extent the 11 kDa Asp₄₀₇ cleavage product, are disulfide linked (Fig. 7).

A diverse set of transmembrane proteins are known to undergo proteolysis in their juxtamembrane regions leading to the release of their extracellular domains into the surrounding milieu (reviewed in 47-49). This process, which has been termed ectodomain shedding, affects a wide variety of proteins, including cytokines, growth factors and their receptors, and adhesion molecules. The unusual P1 Asp-ase activity of BACE secretase / sheddase has not been observed in other cases of ectodomain shedding.

Based on inhibitor studies, ectodomain shedding is predominantly mediated by metalloproteases. Specifically, several members of the ADAM family of metalloproteases (a disintegrin and metalloprotease) have been implicated as ectodomain sheddases (reviewed in 50,51). For example, Kuzbanian (Kuz, ADAM 10) can cleave the Notch ligand Delta and has been shown to have APP α -secretase activity (5). In addition to the ADAM proteases, at least one matrix metalloprotease, MMP-7 (matrilysin) has a functionally relevant role in shedding (52,53). A recent report, suggests that the metalloproteases Meprin A and B can function as sheddases (54). The metalloprotease inhibitors GM6001 (Chemicon International) and TAPI-1 (Peptides International) did not inhibit BACE secretase / sheddase activity in Neuro 2a cells. In a few cases, serine proteases such as proteinase 3 (55) and a putative chymotrypsin-like protease (56) appear to be the enzymes responsible for ectodomain shedding.

The distance of cleavage in BACE from the membrane by BACE secretase / sheddase varies from 5, 48 to 76 amino acids for cleavage after Asp₄₅₁(PQTD↓) (SEQ ID NO :26), Asp₄₀₇ and Asp₃₇₉ (SQDD↓) (SEQ ID NO :24) respectively. In other cases of ectodomain shedding, this distance varies with the substrate and protease

class ranging from intramembranous to 93 amino acids, with the majority of ectodomain shedding resulting from cleavage between 12 to 24 amino acids from the membrane (reviewed in 48).

5 Ectodomain shedding may occur in an intracellular compartment. For example, ADAM-mediated ectodomain shedding by at least two family members, tumor necrosis factor α convertase (TACE) and ADAM 10 may occur in an intracellular compartment in addition to the cell surface (5,57). Intracellular
10 ectodomain shedding may occur by a process recently called Regulated intramembrane proteolysis (Rip)(57). Rip has been shown to occur during the processing of mammalian proteins (e.g. SREBP, Notch, Ire1 and ATF6). For example, SREBP cleavage occurs at a leucine / cysteine bond, three residues into the hydrophobic / transmembrane segment (58,59). Another example of RIP, is the
15 aspartyl protease inhibitor dependent γ -secretase cleavage of APP by a protein complex containing presenilin 1 and presenilin 2(60). This apparent intramembranous cleavage of the A β 40-41 and A β 42-43 peptide bonds within C99 and C83 generates A β 40 and A β 42 and p3-40 and p3-42 (reviewed in 61). Clearly, γ -secretase differs from BACE secretase / sheddase since a substrate-based difluoro ketone inhibitor does not inhibit the later (Fig. 8).

20

The unusual P1 Asp-ase activity of BACE secretase / sheddase is similar to that reported for members of the caspase (cysteinyll-directed aspartate-specific protease) family and the T-lymphocyte serine protease granzyme B (reviewed in 62-64). However, these enzymes cleave their substrates in the cytoplasm or on the
25 cytoplasmic side of organelles. For example, caspase-12 associated with the ER and caspase 2 associated with Golgi cleave substrates on the cytoplasmic surface (65,66). Granzyme B, although secreted from cytotoxic secretory granules, cleave procaspases and other substrates in the cytoplasm of target cells (64). The nonselective pancaspase inhibitor Z-Val-Ala-Asp(OMe)-CH₂F (Calbiochem) at 100 μ M, a

concentration which inhibits the majority of caspases (67), had no effect on the BACE secretase / sheddase activity in Neuro 2a cells.

- 5 Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified without departing from the spirit and nature of the subject invention as defined in the appended claims.

10

LIST OF REFERENCES

1. Selkoe D.J. (1997) *Science* 275:630-631.
2. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. (2000) *JAMA* 283, 1571-1572.
3. Checler F. (1995) *J. Neurochem.* 65, 1431-44.
4. Buxbaum J.D., Liu K.-N., Luo Y., Slack J.L., Stocking K.L., Peshon J.J., Johnson R.S., Castner B.J., Cerretti D.P., and Black R.A. (1998) *J. Biol. Chem.* 273, 27765-27767.
5. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., and Fahrenhol F. (1999) *Proc. Natl. Acad. Sci. USA* 96, 3922-3927.
6. Koike, H., Tomioka, S., Sorimachi, H., Saido, T.C., Maruyama K., Okuyama A., Fujisawa-Sehara A., Ohno, S., Suzuki K., and Ishiura, S. (1999) *Biochem. J.* 343, 371-375.
7. Seidah, N.G. and Chrétien, M. (1999) *Brain Res.* 848, 45-62.
8. Anderson, E.D., Thomas, L., Hayflick, J.S. and Thomas, G. (1993) *J. Biol. Chem.*, 268, 24887-24891
9. Lopez-Perez E., Seidah N.G., and Checler F. (1999) *J. Neurochem.* 73:2056-2062.
10. Marcinkiewicz, M. and Seidah, N.G. (2000) *J. Neurochem.* (in press).
11. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burges T., Louis J.-C., Collins F., Treanor J., Rogers G., and Citron M. (1999) *Science* 286, 735-741.
12. Hussain I., Powell D., Howwlett D.R., Tew D.G., Meek T.D., Chapman C., Gloger I.S., Murphy K.E., Southan C.D., Ryan D.M., Smith T.S., Simmons D.L., Walsh F.S., Dingwall C., and Christie G. (1999) *Mol. Cell. Neurosci.* 14, 419-427.
13. Sinha S., Anderson J.P., Barbour R., Basi G.S., Caccavello R., Davis D., Doan M., Dovey H.F., Frigon N., Hong J., Jacobson-Croak K., Jewett N., Keim P., Knops J., Lieberburg I., Power M., Tan H., Tatsuno G., Tung J., Schenk D., Seubert P., Suomensaaari S.M., Wang S., Walker D., John V., Zhao J., McConlogue L., and John V. (1999) *Nature* 402, 537-540.
14. Yan R., Bienkowski M., Shuck M.E., Miao, H., Tory M.C., Pauley A.M., Brashier J.R., Stratman N.C., Mathews W.R., Buhl A.E., Carter D.B., Tomasselli A.G., Parodi L.A., Heirikson R.L., and Gurney M.E. (1999) *Nature* 402, 533-537.
15. Lin X., Koelsch G., Wu S., Downs D., Dashti A., and Tang J. (2000) *Proc. Natl. Acad. Sci. USA* 97, 1456-1460.
16. Sauder, J.M., Arthur, J.W., and Dunbrack, R.L. Jr (2000) *J. Mol. Biol.* 300, 241-248.
17. Greenfield, J.P., Tsai, J., Gouras, G.K., Hai, B., Thinakaran, G., Checler, F., Sisodia, S.S., Greengard, P., Xu, H. (1999) *Proc. Natl. Acad. Sci. USA* 96, 742-747.
18. Van Gassen, G., Annaert, W. and Van Broeckhoven, C. (2000) *Neurobiol. Disease* 7, 135-151.

19. Wolfe, M.S., Xia, W., Moore, C.L., Leatherwood, D.D., Ostaszewski, B., Rahmati, T., Donkor, I.O., and Selkoe, D.J. (1999) *Biochemistry* 38, 4720-4727.
20. van de Loo, J. W., Creemers, J. W., Bright, N. A., Young, B. D., Roebroek, A. J., and Van de Ven, W. J. (1997) *J. Biol. Chem.* 272, 27116-27123
- 5 21. Benjannet, S., Savaria, D., Laslop, A., Munzer, J.S., Chrétien, M., Marcinkiewicz, M. and Seidah, N. (1997) *J. Biol. Chem.* 272, 26210-26218.
22. Sisodia, S.S., Koo, E.H., Beyreuther, K., Unterbeck, A., and Price, D.L. (1990) *Science* 248, 492-495.
- 10 23. Barelli, H., Lebeau, A., Vizzavona, J., Delaere, P., Chevallier, N., Drouot, C., Marambaud, P., Ancolio, K., Buxbaum, J. D., Khorkova, O., Heroux, J., Sahasrabudhe, S., Martinez, J., Warter, J.-M., Mohr, M. and Checler, F. (1997) *Mol. Medicine* 3, 695-707.
24. Zhong, M., Munzer, J.S., Basak, A., Benjannet, S., Mowla, S.J., Decroly, E., Chrétien, M. and Seidah, N.G. (1999) *J. Biol. Chem.* 274, 33913-33920.
- 15 25. Lussion, J., Vieau, D., Hamelin, J., Day, R., Chrétien, M. and Seidah, N.G. (1993) *Proc. Natl. Acad. Sci. USA* 90, 6691-6695.
26. Seidah, N.G., Mowla, S.J., Hamelin, J., Mamarbachi, A.M., Benjannet, S., Toure, B.B., Basak, A., Munzer, J.S., Marcinkiewicz, J., Zhong, M., Barale, J.C., Lazure, C., Murphy, R.A., Chrétien, M., and Marcinkiewicz, M. (1999) *Proc. Natl. Acad. Sci. USA* 96, 1321-1326.
- 20 27. Touré, B.B., Basak, A., Munzer, J.S., Benjannet, S., Rochemont, J., Lazure, C., Chrétien, M. and Seidah, N.G. (2000) *J. Biol. Chem.* 275, 2349-2358.
28. Rompaey, L. V., Ayoubi, T., Van De Ven, W., and Marynen, P. (1997) *Biochem. J.* 326, 507-514.
- 25 29. Decroly, E., Wouters, S., Dibello, C., Lazure, C., Ruyschaert, J.M. and Seidah, N.G. (1996) *J. Biol. Chem.* 271, 30442-30450.
30. Munzer, J.S., Basak, A., Zhong, M., Mamarbachi, A., Hamelin, J., Savaria, D., Lazure, C., Benjannet, S., Chrétien, M. and Seidah, N.G. (1997) *J. Biol. Chem.* 272, 19672-19681.
- 30 31. Lippincott-Schwartz J., L. Yuan, C. Tipper, M. Amherdt, L. Orci, and R.D. Klausner (1991) *Cell* 67, 601-616.
32. Karaivanova, V.K., and Spiro, R.G. (1998) *Biochem. J.* 329, 511-518.
33. Beisswanger, R., Corbeil, D., Vannier, C., Thiele, C., Dohrmann, U., Kellner, R., Ashman, K., Niehrs, C., Huttner, W.B. (1998) *Proc. Natl. Acad. Sci. USA* 95, 11134-11139.
- 35 34. Xiang, Y., Molloy, S.S., Thomas, L., and Thomas, G. (2000) *Mol. Biol. Cell* 11, 1257-1273.
35. Takahashi, S., Nakagawa, T., Kasai, K., Banno, T., Duguay, S.J., Van, V., Murakami, K. and Nakayama, K. (1995) *J. Biol. Chem.* 270, 26565-26569.
- 40 36. Schweizer, A., Kornfeld, S., Rohrer, J. (1996) *J. Cell Biol.* 132, 577-584.
37. Bowman, E.J., Siebers, A. and Altendorf, K. (1988) *Proc. Natl. Acad. Sci. USA* 85, 7972-7976.
38. Matlin, K.S., and Simons, K. (1983) *Cell* 34, 233-243.

39. Skovronsky, D.M., Moore, D.B., Milla, M.E., Doms, R.W., and Lee, V.M. (1999) *J. Biol. Chem.* **275**, 2568-2575.
40. da Costa, C.A., Ancolio, K., and Checler, F. (1999) *Mol., Med.* **5**, 160-168.
41. Haniu, M., Denis, P., Young, Y., Mendiaz, E.A., Fuller, J., Hui, J.O., Bennett, B.D., Kahn, S., Ross, S., Burgess, T., Katta, V., Rogers, G., Vassar, R. and Citron, M. (2000) *J. Biol. Chem.* **275**, 21099-21106.
42. Capell, A., Steiner, H., Willem, M., Kaiser, H., Meyer, C., Walter, J., Lammich, S., Multhaup, G., and Haass C. (2000) *J. Biol. Chem.* PMID: 10801872
43. Rigot, V.; Andre, F.; Lehmann, M.; Lissitzky, J.C.; Marvaldi, J.; Luis, J. (1999) *Eur. J. Biochem.* **261**, 659-666.
44. Yu, G., Chen, F., Levesque, G., Nishimura, M., Zhang, D.M., Levesque, L., Rogaeva, E., Xu, D., Liang, Y., Duthie, M., St George-Hyslop, P.H., and Fraser, P.E. (1998) *J. Biol. Chem.* **273**, 16470-16475.
45. Mercure, C., Jutras, I., Day, R., Seidah, N.G., and Reudelhuber, T.L. (1996) *Hypertension* **28**, 840-846.
46. Wolfe, M.S. et al. (1998) *J. Med. Chem.* **41**, 6-9.
47. Blobel, C.P. (2000) *Curr Opin Cell Biol* **12** (5), 606-612.
48. Hooper, N.M., Karran, E.H., and Turner, A.J. (1997) *Biochem J.* **321**, 256-279.
49. Massague, J., and Pandiella, A. (1993) *Annu Rev Biochem* **62**, 515-541.
50. Turner, A.J., and Hooper, N.M. (1999) *Biochem Soc Trans* **27** (2), 255-259.
51. Black, R.A., and White, J.M. (1998) *Curr Opin Cell Biol* **10** (5), 654-659.
52. Haro, H. et al. (2000) *J Clin Invest* **105** (2), 143-150.
53. Powell, W.C. et al. (1999) *Curr Biol* **9** (24), 1441-1447.
54. Bertenshaw, G.P. et al. (2001) *J. Biol. Chem.* (In press).
55. Coeshott, C. et al. (1999) *Proc Natl Acad Sci USA* **96** (11), 6261-6266.
56. Lee, M.C. et al. (2000) *Biochem. Biophys. Res. Commun.* **279**, 116-123.
57. Schlöndorff, J. et al. (2000) *Biochem. J.* **347**, 131-138.
58. Ye, J. et al. (2000) *PNAS* **97**, 5123-5128.
59. Brown, M.S. et al. (2000) *Cell* **100**, 391-398.
60. Yu, G. et al. (2000) *Nature* **407**, 48-54.
61. Selkoe, D.J. (1999) *Nature* **399**, A23-A31.
62. Wellington, C.L. and Hayden, M.R. (2000) *Clin. Genet.* **57**, 1-10.
63. Kidd, V.J., Lahti, J.M., and Teitz, T. (2000) seminars in Cell & Developmental Biology, Vol. 11, pp. 191-201.
64. Kam, C.-M., Hudig, D., and Powers, J.C. (2000) *Biochimica et Biophysica Acta* **1477**, 307-323.
65. Nakagawa, T. and Yuan, J. (2000) *The Journal of Cell Biology* **150**, 887-894.
66. Mancini, M. et al. (2000) *J. Cell Biol.* **149**, 603-612.
67. Roy, S. and Nicholson, D.W. (2000) *Methods in Enzymology* **322**, 110-125.

WHAT IS CLAIMED IS :

1. A method of modulating the activity of BACE secretase / sheddase comprising the administration of an agent selected from the group consisting of:

5 an antisense nucleotide that hybridizes with BACE secretase / sheddase mRNA and blocks the translation of that mRNA, a ribozyme that specifically targets and degrades BACE secretase / sheddase mRNA, a peptide that interferes with the binding of BACE secretase / sheddase with BACE, an antibody that functions as an inhibitor of
10 BACE secretase / sheddase activation, an antagonist that functions as an inhibitor of BACE secretase / sheddase activation, an agonist that functions as an activator of BACE secretase / sheddase.

2. A method as defined in claim 1, wherein said modulation consists in the
15 inhibition of BACE secretase / sheddase to prevent cleavage of BACE.

3. A method as defined in claim 2, wherein said agent is an Asp-ase inhibitor.

4. Use of an inhibitor of BACE secretase / sheddase in the making of a
20 medication for preventing cleavage of BACE.

5. A use as defined in claim 4, wherein said inhibitor is selected from the group consisting of:

25 an antisense nucleotide that hybridizes with BACE secretase / sheddase mRNA and blocks the translation of that mRNA, a ribozyme that specifically targets and degrades BACE secretase / sheddase mRNA, a peptide that interferes with the binding of BACE secretase / sheddase with BACE, an antibody that functions as an inhibitor of

BACE secretase / sheddase activation, and an antagonist that functions as an inhibitor of BACE secretase / sheddase activation.

6. A use as defined in claim 5, wherein said inhibitor is an Asp-ase inhibitor.

5

7. A use as defined in claim 5 or 6 for the treatment of a neurodegenerative disorder that is characterized by the generation of A β protein.

8. A use as defined in claim 7, wherein said neurodegenerative disorder is Alzheimer's Disease.

10

9. A method for the identification of an agent that can alter the ability of BACE secretase / sheddase to associate with and process a known substrate, comprising :

15

in a reaction mixture, allowing said BACE secretase / sheddase to bind to said known substrate of said BACE secretase / sheddase in the presence of an agent to be tested; and


20

measuring the production of BACE C-terminal cleavage products, shed BACE or A β in the presence of said agent to be tested, and comparing same under conditions when said agent to be tested is absent from the reaction mixture.

- 25 10. A method as defined in claim 9, wherein said known substrate is BACE, BACE fragments, or the indirect substrate β APP.


11. A method as defined in claim 10, wherein said known substrate is labeled with a detectable moiety.
12. A method as defined in claim 11, wherein said detectable moiety is a radionuclide, an antibody or fluorescent label.
13. A method as defined in any one of claims 9-12, which is automated.
14. Use of a method as defined in claim 13 for high through-put screening of a number of agents.
15. A method of determining whether an individual is at risk of developing a neurodegenerative disorder that is characterized by the generation of A β protein, comprising :
 - providing a tissue or fluid sample from said individual; and
 - determining whether the level of BACE C-terminal cleavage products, shed BACE or A β in said sample is higher than the level in a sample of a healthy subject, as an indication that the individual is at risk of developing a neurodegenerative disorder that is characterized by the generation of A β protein.
16. A method as defined in claim 15, wherein said tissue or fluid sample is cerebrospinal fluid (CSF) or blood platelets.
17. A method as defined in claim 15 or 16, wherein said neurodegenerative disorder is Alzheimer's Disease.

18. A kit comprising a container or containers comprising BACE secretase / sheddase and at least one substrate selected from the group consisting of BACE, BACE fragments, or the indirect substrate β APP.




SUBSTITUTE SHEET (RULE 26)


2/11



3/11




4 / 11




SUBSTITUTE SHEET (RULE 26)

5 / 11




SUBSTITUTE SHEET (RULE 26)

6 / 11



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

8/11



SUBSTITUTE SHEET (RULE 26)


9/11



Ab: BACE 41 Ab: BACE 41

FIG. 9

SUBSTITUTE SHEET (RULE 26)



355
 380 I
 4
 15 20
 QSFRTILPQQYLRPVEDVATSQDD CYKFAVSQSSSTGTVMGAVIM




FIG. 10A





FIG. 10B

10/11


SUBSTITUTE SHEET (RULE 26)

///



394 407 420 8

MGAVIMEGFYVFD RARKRIGFAVSACHVHDEFRTAAVEGPFVT



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 01/01118

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N9/64 C07K14/81 C12N15/11 A61K38/55 A61K39/00 C12Q1/37 G01N33/50		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K A61K C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DUGUAY STEPHEN J ET AL: "Post-translational processing of the insulin-like growth factor-2 precursor: Analysis of O-glycosylation and endoproteolysis" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 29, 17 July 1998 (1998-07-17), pages 18443-18451, XP002159286 ISSN: 0021-9258 Experimental Procedures, page 18444, RH column, second paragraph abstract <div style="text-align: center; margin-top: 20px;">-/--</div>	1
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
* Special categories of cited documents:		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*Z* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">26 November 2001</div>		Date of mailing of the international search report <div style="text-align: center;">13/12/2001</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Bretherick, J</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/01/01118

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEUBERT P ET AL: "ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMER'S BETA-PEPTIDE FROM BIOLOGICAL FLUIDS" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 359, no. 6393, 24 September 1992 (1992-09-24), pages 325-327, XP000616173 ISSN: 0028-0836 the whole document	15-17
X	DE 196 41 180 A (SCHERING AG) 26 March 1998 (1998-03-26) the whole document, especially examples 6 and 7	18
X	WO 98 13488 A (SCHERING AG ; DYRKS THOMAS (DE); HAERTEL MARION (DE); TURNER JONATH) 2 April 1998 (1998-04-02) the whole document, especially examples 6, 7 and claims	18
X	LIN XINLI ET AL: "Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 4, 15 February 2000 (2000-02-15), pages 1456-1460, XP002159619 ISSN: 0027-8424 the whole document	18
P,X	CREEMERS J. ET AL.: "Processing of beta.-secretase by Furin and Other Members of the Proprotein Convertase Family" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 6, - February 2001 (2001-02) pages 4211-4217, XP002183895 the whole document	1-18
P,X	ERMOLIEFF ET AL: "Proteolytic Activation of Recombinant Pro-memapsin 2 (Pro-.beta.-secretase) Studied with New Fluorogenic Substrates" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 39, September 2000 (2000-09), pages 12450-12456, XP002162934 ISSN: 0006-2960 the whole document, especially abstract and discussion.	1-18
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 01/01118

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SKOVRONSKY D M ET AL: "beta-Secretase revealed: starting gate for race to novel therapies for Alzheimer's disease" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 5, May 2000 (2000-05), pages 161-163, XP004198178 ISSN: 0165-6147 the whole document ---	
A	POTTER ET AL.: "The Potential of BACE inhibitors for Alzheimer's Therapy" NATURE BIOTECHNOLOGY, vol. 18, - February 2000 (2000-02) pages 125-126, XP002183896 the whole document ---	
A	VASSAR R ET AL: "BETA-SECRETASE CLEAVAGE OF ALZHEIMER'S AMYLOID PRECURSOR PROTEIN BY THE TRANSMEMBRANE ASPARTIC PROTEASE BACE" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5440, 1999, pages 735-741, XP000914811 ISSN: 0036-8075 the whole document ---	
A	HANIU M ET AL: "CHARACTERIZATION OF ALZHEIMER'S BETA-SECRETASE PROTEIN BACE A PEPSIN FAMILY MEMBER WITH UNUSUAL PROPERTIES" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21099-21106, XP001022144 ISSN: 0021-9258 the whole document -----	

INTERNATIONAL SEARCH REPORT

on patent family members

International Application No

PCT/ 1/01118

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19641180	A	26-03-1998	DE 19641180 A1	26-03-1998
			AU 4775797 A	17-04-1998
			WO 9813488 A2	02-04-1998
WO 9813488	A	02-04-1998	DE 19641180 A1	26-03-1998
			AU 4775797 A	17-04-1998
			WO 9813488 A2	02-04-1998

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-3 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)